UK Treasury Rejects Proposal to Cut VAT on Public EV Charging to 5 Amid Interdepartmental Disagreement Fed Rate Hike Odds Rising on Prediction Markets for July 2027 Japans Gold Exports Reach Record 25 Billion Smuggled Metal May Be Included BP Removes Chairman Albert Manifold Amid Board Complaints An AI Stock Outpaces Nvidia Since January What Investors Should Know Micron Technology Surges as UBS Triples Price Target on AI Demand Nears 1 Trillion Valuation Annovis Bio Q1 2026 Earnings EPS Misses Estimates as PreClinical Spending Intensifies KORE Q1 2026 Earnings Earnings Miss Estimates by Wide Margin Stock Reacts Modestly Columbia Sportswear COLM Q1 2026 Earnings Massive EPS Surprise Powers Stock Rally Biglari Holdings Q1 2025 Earnings Strong EPS Performance Amid Limited Visibility Park Hotels Resorts Inc PK Q1 2026 Earnings Massive EPS Beat Highlights Strong Operating Performance Beam Therapeutics Inc BEAM Q1 2026 Earnings Narrowing Losses Drive Positive Market Response Ascentage Pharma AAPG Advances 22 as Biotech Sector Finds Footing 707 Cayman Holdings JEM Climbs Nearly 3 as Momentum Builds Near Key Resistance Brera Holdings PLC SLMT Slides 43 Amidst Market Pressure Key Support Levels in Focus Xcel Energy Junior Subordinated Notes XELLL Hold Steady Near Key Support Sabesp SBS Slips Lower as Utility Stock Tests Support Near 538 ADC Therapeutics Q1 2026 Earnings Narrower Loss Beats Expectations as Pipeline Progress Continues FENG Q3 2024 Earnings Net Loss Deepens as Advertising Headwinds Persist PDLB Q4 2025 Earnings Significant EPS Beat Belies Stock Decline Olema Pharmaceuticals Inc OLMA Q1 2026 Earnings NarrowerThanExpected Loss Amid Ongoing Clinical Progress Community Health Systems Q1 2026 Earnings Significant EPS Miss Stock Gains on Operational Detail GHC Q1 2026 Earnings EPS Surges Past Estimates by 268 Free Fish Fillet Program Offers Lifeline to Maines Groundfishing Industry Amid Rising Costs EW Q1 2026 Earnings EPS Beat Drives Stock Higher Amid Limited Revenue Disclosure Inhibrx Biosciences INBX Surges Over 5 as Biotech Momentum Builds